[1] Skirecki T, Cavaillon J. M. 2019.Inner sensors of endotoxin – implications for sepsis research and therapy.FEMS Microbiology Reviews 43:239-256
[2] Finfer S., Machado, F.R. 2016. The Global Epidemiology of Sepsis. Does It Matter That We Know So Little?. American journal of respiratory and critical care medicine 193: 228-230.
[3] Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G.R., Chiche J.D., Coopersmith C.M., Hotchkiss R.S., Levy M.M., Marshall J.C., Martin G.S., Opal S.M., Rubenfeld G.D., van der Poll T., Vincent J.L. Angus D.C. 2016. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama 315: 801-810.
[4] Hotchkiss R.S., Karl I.E. 2003. The pathophysiology and treatment of sepsis. The New England journal of medicine 348: 138-150.
[5] Pantović-Stefanović M., Petronijević N., Dunjić-Kostić B., Velimirović M., Nikolić T., Jurišić V., Lačković M., Damjanović A., Totić-Poznanović S., Jovanović A.A., Ivković M. 2018. sVCAM-1, sICAM-1, TNF-α and IL-6 levels in bipolar disorder type I: Acute, longitudinal and therapeutic implications. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 19: S41-S51.
[6] Song R., Kim J., Yu D., Park C., Park J. 2012. Kinetics of IL-6 and TNF-α changes in a canine model of sepsis induced by endotoxin. Veterinary immunology and immunopathology 146: 143-149.
[7] Alicja K. P., Aleksandra C.T., Agnieszka S.K., Maciej K. B., Alina B. 2020. Biochemical Parameters in Cognitive Functions. Neuropsychiatric Diseaseand Treatment. 16:2479-2489.
[8] Kang S., Tanaka T., Kishimoto T. 2015. Therapeutic uses of anti-interleukin-6 receptor antibody. International immunology 27: 21-29.
[9] Rau S., Kohn B., Richter C., Fenske N., Küchenhoff H., Hartmann K., Härtle S., Kaspers B., Hirschberger J. 2007. Plasma interleukin-6 response is predictive for severity and mortality in canine systemic inflammatory response syndrome and sepsis. Veterinary clinical pathology 36: 253-260.
[10] Watanabe E., Hirasawa H., Oda S., Matsuda K., Hatano M., Tokuhisa T. 2005. Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms. Critical care medicine 33 : 89-97; discussion 242-243.
[11] Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. 1993. Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
[12] Arbabi-Ghahroudi M. 2017. Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook. Frontiers in immunology 8: 1589.
[13] Muyldermans S. 2013. Nanobodies: natural single-domain antibodies. Annual review of biochemistry 82: 775-797.
[14] Kontermann R.E. 2012. Dual targeting strategies with bispecific antibodies. mAbs 4: 182-197.
[15] Fleischmann C., Scherag A., Adhikari N.K., Hartog C.S., Tsaganos T., Schlattmann P., Angus D.C., Reinhart K. 2016. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. American journal of respiratory and critical care medicine 193 : 259-272.
[16] Hotchkiss R.S., Monneret G., Payen D. 2013. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. The Lancet. Infectious diseases 13: 260-268.